TD Asset Management »

Rapport Therapeutics shares owned by TD Asset Management

Quarter-by-quarter ownership of Rapport Therapeutics shares owned by TD Asset Management from 13F filings

Historical chart of TD Asset Management investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by TD Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by TD Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $2.4M 102k 23.26

More positions owned by TD Asset Management

Microsoft Corporation (MSFT)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Rbc Cad (RY)
Toronto Dominion Bk Ont Com New (TD)
Meta Platforms Cl A (META)
Canadian Pacific Kansas City (CP)
Amazon (AMZN)
Bank Of Montreal Cadcom (BMO)
Canadian Natural Resources (CNQ)
Broadcom (AVGO)
Canadian Natl Ry (CNI)
Enbridge (ENB)
Eli Lilly & Co. (LLY)

View all positions for TD Asset Management

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
T. Rowe Price Associates
Alliancebernstein
Perceptive Advisors
Citadel Advisors
Artal Group
Logos Global Management
Woodline Partners
Millennium Management
TD Asset Management
Manufacturers Life Insurance Company

View all funds holding Rapport Therapeutics